 Adrenergic beta-Antagonists
"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
| Descriptor ID |
D000319
|
| MeSH Number(s) |
D27.505.519.625.050.200.200 D27.505.696.577.050.200.200
|
| Concept/Terms |
Adrenergic beta-Antagonists- Adrenergic beta-Antagonists
- Adrenergic beta Antagonists
- beta-Antagonists, Adrenergic
- beta-Adrenergic Receptor Blockaders
- Blockaders, beta-Adrenergic Receptor
- Receptor Blockaders, beta-Adrenergic
- beta Adrenergic Receptor Blockaders
- beta-Adrenergic Blockers
- Blockers, beta-Adrenergic
- beta Adrenergic Blockers
- beta-Blockers, Adrenergic
- Adrenergic beta-Blockers
- beta Blockers, Adrenergic
- Adrenergic beta-Receptor Blockaders
- Adrenergic beta Receptor Blockaders
- Blockaders, Adrenergic beta-Receptor
- beta-Receptor Blockaders, Adrenergic
- beta-Adrenergic Blocking Agents
- Agents, beta-Adrenergic Blocking
- Blocking Agents, beta-Adrenergic
- beta Adrenergic Blocking Agents
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 1 | 2 | | 1990 | 4 | 0 | 4 | | 1991 | 1 | 0 | 1 | | 1992 | 3 | 2 | 5 | | 1993 | 3 | 0 | 3 | | 1994 | 5 | 1 | 6 | | 1995 | 2 | 0 | 2 | | 1996 | 8 | 4 | 12 | | 1997 | 5 | 1 | 6 | | 1998 | 6 | 4 | 10 | | 1999 | 4 | 2 | 6 | | 2000 | 7 | 0 | 7 | | 2001 | 9 | 8 | 17 | | 2002 | 3 | 2 | 5 | | 2003 | 5 | 3 | 8 | | 2004 | 7 | 2 | 9 | | 2005 | 3 | 7 | 10 | | 2006 | 4 | 7 | 11 | | 2007 | 7 | 3 | 10 | | 2008 | 9 | 2 | 11 | | 2009 | 5 | 1 | 6 | | 2010 | 8 | 4 | 12 | | 2011 | 7 | 5 | 12 | | 2012 | 6 | 5 | 11 | | 2013 | 10 | 2 | 12 | | 2014 | 4 | 4 | 8 | | 2015 | 4 | 3 | 7 | | 2016 | 3 | 1 | 4 | | 2017 | 3 | 5 | 8 | | 2018 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.
-
Chow SL, Page RL, Depre C. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. Expert Rev Cardiovasc Ther. 2018 Jul; 16(7):515-526.
-
Allen LA, Tang F, Jones P, Breeding T, Ponirakis A, Turner SJ. Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: insights from the NCDR PINNACLE® registry. BMC Cardiovasc Disord. 2018 05 03; 18(1):80.
-
Bhatt SP, Vegas-Sánchez-Ferrero G, Rahaghi FN, MacLean ES, Gonzalez-Serrano G, Come CE, Kinney GL, Hokanson JE, Budoff MJ, Cuttica MJ, Wells JM, Estépar RSJ, Washko GR. Cardiac Morphometry on Computed Tomography and Exacerbation Reduction with ß-Blocker Therapy in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 12 01; 196(11):1484-1488.
-
Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 01 15; 121(2):256-261.
-
Gurwitz JH, Magid DJ, Smith DH, Tabada GH, Sung SH, Allen LA, McManus DD, Goldberg RJ, Tisminetzky M, Go AS. Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. J Am Geriatr Soc. 2017 Dec; 65(12):2610-2618.
-
Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, Casaburi R, Cooper JA, Curtis JL, Dransfield M, Han MK, Make B, Marchetti N, Martinez F, Lazarus S, Niewoehner D, Scanlon PD, Sciurba F, Scharf S, Reed RM, Washko G, Woodruff P, McEvoy C, Aaron S, Sin D, Criner GJ. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res. 2017 06 19; 18(1):124.
-
Pitts R, Daugherty SL, Tang F, Jones P, Ho PM, Tsai TT, Spertus J, Maddox TM. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry. Clin Cardiol. 2017 Jun; 40(6):347-355.
-
Chen DC, Singh GD, Armstrong EJ, Waldo SW, Laird JR, Amsterdam EA. Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease. Am J Cardiol. 2017 Apr 15; 119(8):1146-1152.
-
Qian H, Patriarchi T, Price JL, Matt L, Lee B, Nieves-Cintrón M, Buonarati OR, Chowdhury D, Nanou E, Nystoriak MA, Catterall WA, Poomvanicha M, Hofmann F, Navedo MF, Hell JW. Phosphorylation of Ser1928 mediates the enhanced activity of the L-type Ca2+ channel Cav1.2 by the ß2-adrenergic receptor in neurons. Sci Signal. 2017 01 24; 10(463).
-
Piccini JP, Allen LA. Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet. JACC Heart Fail. 2017 02; 5(2):107-109.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|